Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

GT Biopharma (GTBP) Income from Continuing Operations (2016 - 2021)

GT Biopharma (GTBP) has disclosed Income from Continuing Operations for 12 consecutive years, with 18200000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Income from Continuing Operations fell 219.55% to 18200000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was 58201000.0, a 3227.4% decrease, with the full-year FY2025 number at 12426000.0, up 11.0% from a year prior.
  • Income from Continuing Operations was 18200000.0 for Q4 2021 at GT Biopharma, down from 5922000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15224000.0 in Q4 2020 to a low of 235783000.0 in Q3 2018.
  • A 5-year average of 26006000.0 and a median of 5058000.0 in 2017 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 3538.46% in 2017, then skyrocketed 1135.65% in 2020.
  • GT Biopharma's Income from Continuing Operations stood at 4575000.0 in 2017, then tumbled by 5053.73% to 235783000.0 in 2018, then surged by 99.38% to 1470000.0 in 2019, then surged by 1135.65% to 15224000.0 in 2020, then plummeted by 219.55% to 18200000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Income from Continuing Operations are 18200000.0 (Q4 2021), 5922000.0 (Q3 2021), and 4381000.0 (Q2 2021).